PMID- 12869031
OWN - NLM
STAT- MEDLINE
DCOM- 20030916
LR  - 20221222
IS  - 0009-9104 (Print)
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Linking)
VI  - 133
IP  - 2
DP  - 2003 Aug
TI  - Prospective audit of adverse reactions occurring in 459 primary 
      antibody-deficient patients receiving intravenous immunoglobulin.
PG  - 247-51
AB  - Intravenous immunoglobulin (IVIG) is used as the standard replacement therapy for 
      patients with primary antibody deficiencies. A previous study of adverse 
      reactions in patients self-infusing at home over 1 year showed an overall 
      reaction rate of 0.7%. A larger prospective study is reported here, involving a 
      greater number of immunology centres and including children and adults who 
      received infusions from medical or nursing staff as well as those self-infusing. 
      Four hundred and fifty-nine patients were entered into this study and 13 508 
      infusions were given. The study showed that no severe reactions occurred and the 
      reaction rate was low at 0.8%. This figure could have been lower, 0.5%, if 
      predisposing factors responsible for some reactions had been considered before 
      infusion. In conclusion, the study shows the importance of ongoing training for 
      patients and staff to recognize the predisposing factors to prevent avoidable 
      reactions. Because none of these reactions were graded as severe, the present 
      guidance to prescribe self-injectable adrenaline for patients infusing outside 
      hospital should be reviewed.
FAU - Brennan, V M
AU  - Brennan VM
AD  - Department of Immunology, Oxford Radcliffe Hospital, Oxford UK.
FAU - Salome-Bentley, N J
AU  - Salome-Bentley NJ
FAU - Chapel, H M
AU  - Chapel HM
CN  - Immunology Nurses Study
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects
MH  - Immunologic Deficiency Syndromes/*therapy
MH  - Infections/complications
MH  - Male
MH  - Medical Audit
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC1808773
EDAT- 2003/07/19 05:00
MHDA- 2003/09/17 05:00
PMCR- 2004/08/01
CRDT- 2003/07/19 05:00
PHST- 2003/07/19 05:00 [pubmed]
PHST- 2003/09/17 05:00 [medline]
PHST- 2003/07/19 05:00 [entrez]
PHST- 2004/08/01 00:00 [pmc-release]
AID - 2199 [pii]
AID - 10.1046/j.1365-2249.2003.02199.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2003 Aug;133(2):247-51. doi: 10.1046/j.1365-2249.2003.02199.x.